Arsenio Fernández-López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arsenio Fernández-López has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Pedro Calvo
11 shared publicationsBerta Anuncibay-Soto
Neural Therapies S.L., Edificio Institutos de Investigación, Local B43. Campus de Vegazana, León, Spain
10 shared publications- Diego Pérez-Rodríguez
Area de Biologia Celular, Instituto de Biomedicina, Universidad de León, León, Spain
10 shared publications Victoria Revilla
Departamento de Biologı́a Celular y Anatomı́a, Facultad de Biologı́a, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain
10 shared publications- Severiano Dos-Anjos
Area de Biología Celular, Instituto de Biomedicina, Universidad de León, 24071, León, Spain
9 shared publications Beatriz Martínez-Villayandre
8 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Correction: Sustained Transcriptional Response to Lipopolysaccharide and Interleukin-4 in an Immortalized Mouse Microglial Cell Line
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Open AccessCorrection: Sustained Transcriptional Response to Lipopolysaccharide and Interleukin-4 in an Immortalized Mouse Microglial Cell Line
- Open Access
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 425
Sustained Transcriptional Response to Lipopolysaccharide and Interleukin-4 in an Immortalized Mouse Microglial Cell Line
In an attempt to identify markers that better characterize microglial states and to search for potential therapeutic targets, we performed a study using the IMG cell line as an in vitro microglial model. Specifically, we tested its response to several pro-inflammatory stimuli (lipopolysaccharide, interferon gamma, and tumor necrosis factor) and an anti-inflammatory stimulus (Interleukin-4) after 12 and 24 h of incubation. We performed RNA sequencing to identify genes modified at both incubation times (i.e., genes with sustained changes in the window between 12 and 24 h) that could reflect sustained microglial transcriptional responses. We also used Gene Ontology (GO) analysis to identify the most relevant pathways modified by these stimuli. RNA sequencing revealed four gene sets: ( 1) common genes that respond similarly to IL-4 and LPS, (2) specific LPS responders, (3) specific IL-4 responders, and (4) genes that exhibit LPS-induced upregulation and IL-4-induced downregulation, and vice versa (opposite responders). We hypothesize that the common gene set represents a general microglia response to pathological conditions, while the LPS- and IL-4-responder gene sets define specific microglial states under pro- and anti-inflammatory stimuli, respectively. We further propose that opposite responder genes act as metabolic switches between certain microglial states. The GO analysis indicated that LPS strongly upregulates biological processes related to the innate immune response, while IL-4 upregulates pathways related to repair, metabolic reprogramming, and cellular cooperation. Finally, the transcriptional response of IMG cells closely mirrored that of primary microglia, revealing highly similar gene expression and GO term profiles under LPS stimulation. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 425
Open AccessSustained Transcriptional Response to Lipopolysaccharide and Interleukin-4 in an Immortalized Mouse Microglial Cell Line
In an attempt to identify markers that better characterize microglial states and to search for potential therapeutic targets, we performed a study using the IMG cell line as an in vitro microglial model. Specifically, we tested its response to several pro-inflammatory stimuli (lipopolysaccharide, interferon gamma, and tumor necrosis factor) and an anti-inflammatory stimulus (Interleukin-4) after 12 and 24 h of incubation. We performed RNA sequencing to identify genes modified at both incubation times (i.e., genes with sustained changes in the window between 12 and 24 h) that could reflect sustained microglial transcriptional responses. We also used Gene Ontology (GO) analysis to identify the most relevant pathways modified by these stimuli. RNA sequencing revealed four gene sets: ( 1) common genes that respond similarly to IL-4 and LPS, (2) specific LPS responders, (3) specific IL-4 responders, and (4) genes that exhibit LPS-induced upregulation and IL-4-induced downregulation, and vice versa (opposite responders). We hypothesize that the common gene set represents a general microglia response to pathological conditions, while the LPS- and IL-4-responder gene sets define specific microglial states under pro- and anti-inflammatory stimuli, respectively. We further propose that opposite responder genes act as metabolic switches between certain microglial states. The GO analysis indicated that LPS strongly upregulates biological processes related to the innate immune response, while IL-4 upregulates pathways related to repair, metabolic reprogramming, and cellular cooperation. Finally, the transcriptional response of IMG cells closely mirrored that of primary microglia, revealing highly similar gene expression and GO term profiles under LPS stimulation. Graphical Abstract
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (9) , 4322-4330
Critical ischemia duration thresholds in the rat middle cerebral artery occlusion model: Implications for drug screening
The growing incidence of stroke and the absence of drugs to fight its devastating consequences highlight the urgent need to identify therapeutic agents. The middle cerebral artery occlusion model is commonly used to screen new putative anti-stroke agents in rodents. However, differences in ischemia and reperfusion times result in differences in neurological deficit and infarct volume, two of the most commonly used parameters in preclinical assays. These differences make it difficult to select the optimal screening conditions. Here, we report a parallel study comparing behavior, infarct volume, and transcriptomic outcomes after 15 days of reperfusion in a rat middle cerebral artery occlusion model with mild (45 minutes) and moderate (60 minutes) ischemia. The behavioral assays revealed that motor and sensory responses, but not the infarct volume, are sensitive to slight variations in the time of ischemia. The transcriptomic profiling demonstrated striking changes in the number of up- and downregulated genes between mild and moderate ischemia. Gene Ontology analysis supported noteworthy differences between mild and moderate ischemia, particularly in genes related to protein synthesis and processing. Complementary quantitative polymerase chain reaction and western blotting assays confirmed these differences. These results indicate a threshold between mild and moderate ischemia, where changes in behavior and molecular responses mirror a substantial alteration in brain cell biology that appears critical for molecular screening. These findings pinpoint the critical role of selecting the appropriate ischemia model in preclinical stroke studies to enhance the translational relevance of the results and therapeutic strategies.
- 25 November 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (9) , 4322-4330
Open AccessCritical ischemia duration thresholds in the rat middle cerebral artery occlusion model: Implications for drug screening
The growing incidence of stroke and the absence of drugs to fight its devastating consequences highlight the urgent need to identify therapeutic agents. The middle cerebral artery occlusion model is commonly used to screen new putative anti-stroke agents in rodents. However, differences in ischemia and reperfusion times result in differences in neurological deficit and infarct volume, two of the most commonly used parameters in preclinical assays. These differences make it difficult to select the optimal screening conditions. Here, we report a parallel study comparing behavior, infarct volume, and transcriptomic outcomes after 15 days of reperfusion in a rat middle cerebral artery occlusion model with mild (45 minutes) and moderate (60 minutes) ischemia. The behavioral assays revealed that motor and sensory responses, but not the infarct volume, are sensitive to slight variations in the time of ischemia. The transcriptomic profiling demonstrated striking changes in the number of up- and downregulated genes between mild and moderate ischemia. Gene Ontology analysis supported noteworthy differences between mild and moderate ischemia, particularly in genes related to protein synthesis and processing. Complementary quantitative polymerase chain reaction and western blotting assays confirmed these differences. These results indicate a threshold between mild and moderate ischemia, where changes in behavior and molecular responses mirror a substantial alteration in brain cell biology that appears critical for molecular screening. These findings pinpoint the critical role of selecting the appropriate ischemia model in preclinical stroke studies to enhance the translational relevance of the results and therapeutic strategies.
- Open Access
- 30 January 2023
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (9) , 1961-1967
Neuroprotective effects of meloxicam on transient brain ischemia in rats: the two faces of anti-inflammatory treatments
JOURNAL/nrgr/04.03/01300535-202309000-00022/figure1/v/2026-05-25T155815Z/r/image-tiff The inflammatory response plays an important role in neuroprotection and regeneration after ischemic insult. The use of non-steroidal anti-inflammatory drugs has been a matter of debate as to whether they have beneficial or detrimental effects. In this context, the effects of the anti-inflammatory agent meloxicam have been scarcely documented after stroke, but its ability to inhibit both cyclooxygenase isoforms (1 and 2) could be a promising strategy to modulate post-ischemic inflammation. This study analyzed the effect of meloxicam in a transient focal cerebral ischemia model in rats, measuring its neuroprotective effect after 48 hours and 7 days of reperfusion and the effects of the treatment on the glial scar and regenerative events such as the generation of new progenitors in the subventricular zone and axonal sprouting at the edge of the damaged area. We show that meloxicam’s neuroprotective effects remained after 7 days of reperfusion even if its administration was restricted to the two first days after ischemia. Moreover, meloxicam treatment modulated glial scar reactivity, which matched with an increase in axonal sprouting. However, this treatment decreased the formation of neuronal progenitor cells. This study discusses the dual role of anti-inflammatory treatments after stroke and encourages the careful analysis of both the neuroprotective and the regenerative effects in preclinical studies.
- 30 January 2023
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (9) , 1961-1967
Open AccessNeuroprotective effects of meloxicam on transient brain ischemia in rats: the two faces of anti-inflammatory treatments
JOURNAL/nrgr/04.03/01300535-202309000-00022/figure1/v/2026-05-25T155815Z/r/image-tiff The inflammatory response plays an important role in neuroprotection and regeneration after ischemic insult. The use of non-steroidal anti-inflammatory drugs has been a matter of debate as to whether they have beneficial or detrimental effects. In this context, the effects of the anti-inflammatory agent meloxicam have been scarcely documented after stroke, but its ability to inhibit both cyclooxygenase isoforms (1 and 2) could be a promising strategy to modulate post-ischemic inflammation. This study analyzed the effect of meloxicam in a transient focal cerebral ischemia model in rats, measuring its neuroprotective effect after 48 hours and 7 days of reperfusion and the effects of the treatment on the glial scar and regenerative events such as the generation of new progenitors in the subventricular zone and axonal sprouting at the edge of the damaged area. We show that meloxicam’s neuroprotective effects remained after 7 days of reperfusion even if its administration was restricted to the two first days after ischemia. Moreover, meloxicam treatment modulated glial scar reactivity, which matched with an increase in axonal sprouting. However, this treatment decreased the formation of neuronal progenitor cells. This study discusses the dual role of anti-inflammatory treatments after stroke and encourages the careful analysis of both the neuroprotective and the regenerative effects in preclinical studies.
- Open Access
- 1 July 2022
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (2) , 342-343
PANoptosis: new insights in regulated cell death in ischemia/reperfusion models
- 1 July 2022
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (2) , 342-343
Open AccessPANoptosis: new insights in regulated cell death in ischemia/reperfusion models
- 21 June 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1662-1667
Low-cost drone for confined space inspection
This work shows the design and implementation of a low-cost drone for use in confined spaces. The drone is made with commercial materials and customized elements through 3D printing. The system is robust and lightweight. The work focuses especially on the design of the exoskeleton. The system reaches a weight of 895.3 g and an autonomy of about 13 min. This calculation is performed analytically and validated through commercial software.
- 21 June 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1662-1667
Low-cost drone for confined space inspection
This work shows the design and implementation of a low-cost drone for use in confined spaces. The drone is made with commercial materials and customized elements through 3D printing. The system is robust and lightweight. The work focuses especially on the design of the exoskeleton. The system reaches a weight of 895.3 g and an autonomy of about 13 min. This calculation is performed analytically and validated through commercial software.
- Open Access
- 8 March 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (3) , 356
Understanding microRNAs in the Context of Infection to Find New Treatments against Human Bacterial Pathogens
The development of RNA-based anti-infectives has gained interest with the successful application of mRNA-based vaccines. Small RNAs are molecules of RNA of <200 nucleotides in length that may control the expression of specific genes. Small RNAs include small interference RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), or microRNAs (miRNAs). Notably, the role of miRNAs on the post-transcriptional regulation of gene expression has been studied in detail in the context of cancer and many other genetic diseases. However, it is also becoming apparent that some human miRNAs possess important antimicrobial roles by silencing host genes essential for the progress of bacterial or viral infections. Therefore, their potential use as novel antimicrobial therapies has gained interest during the last decade. The challenges of the transport and delivery of miRNAs to target cells are important, but recent research with exosomes is overcoming the limitations in RNA-cellular uptake, avoiding their degradation. Therefore, in this review, we have summarised the latest developments in the exosomal delivery of miRNA-based therapies, which may soon be another complementary treatment to pathogen-targeted antibiotics that could help solve the problem caused by multidrug-resistant bacteria.
- 8 March 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (3) , 356
Open AccessUnderstanding microRNAs in the Context of Infection to Find New Treatments against Human Bacterial Pathogens
The development of RNA-based anti-infectives has gained interest with the successful application of mRNA-based vaccines. Small RNAs are molecules of RNA of <200 nucleotides in length that may control the expression of specific genes. Small RNAs include small interference RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), or microRNAs (miRNAs). Notably, the role of miRNAs on the post-transcriptional regulation of gene expression has been studied in detail in the context of cancer and many other genetic diseases. However, it is also becoming apparent that some human miRNAs possess important antimicrobial roles by silencing host genes essential for the progress of bacterial or viral infections. Therefore, their potential use as novel antimicrobial therapies has gained interest during the last decade. The challenges of the transport and delivery of miRNAs to target cells are important, but recent research with exosomes is overcoming the limitations in RNA-cellular uptake, avoiding their degradation. Therefore, in this review, we have summarised the latest developments in the exosomal delivery of miRNA-based therapies, which may soon be another complementary treatment to pathogen-targeted antibiotics that could help solve the problem caused by multidrug-resistant bacteria.
- Open Access
- 8 July 2021
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 17 (2) , 302-303
Celeboxib-mediated neuroprotection in focal cerebral ischemia: an interplay between unfolded protein response and inflammation
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
- 8 July 2021
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 17 (2) , 302-303
Open AccessCeleboxib-mediated neuroprotection in focal cerebral ischemia: an interplay between unfolded protein response and inflammation
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
- Open Access
The neuroprotective effect of meloxicam in a transient ischemia model involves an increase in axonal sprouting but a decrease in new neuron formation after 7 days of reperfusion
The inflammatory response plays an important role in neuroprotection and regeneration after ischemic insult. The use of non-steroidal anti-inflammatory drugs has been a matter of debate as to whether they have beneficial or detrimental effects. In this context, the effects of the anti-inflammatory agent meloxicam have been scarcely documented after stroke, but its ability to inhibit both cyclooxygenase isoforms (1 and 2) could be a promising strategy to modulate post-ischemic inflammation. This study analyzed the effect of the anti-inflammatory agent meloxicam in a transient focal ischemia model in rats, measuring its neuroprotective effect after 48 hours and 7 days of reperfusion and the effects of the treatment on the glial scar and regenerative events such as the generation of new progenitors in the subventricular zone and axonal sprouting at the edge of the damaged area. We show that meloxicam’s neuroprotective effects remained after 7 days of reperfusion even if its administration was restricted to the two first days after ischemia. Moreover, meloxicam treatment modulated glial scar reactivity, which matched with an increase in axonal sprouting. However, this treatment decreased the formation of neuronal progenitor cells. This study discusses the dual role of anti-inflammatory treatments after stroke and encourages the careful analysis of both the neuroprotective and the regenerative effects in preclinical studies. Abstract Figure:
Open AccessThe neuroprotective effect of meloxicam in a transient ischemia model involves an increase in axonal sprouting but a decrease in new neuron formation after 7 days of reperfusion
The inflammatory response plays an important role in neuroprotection and regeneration after ischemic insult. The use of non-steroidal anti-inflammatory drugs has been a matter of debate as to whether they have beneficial or detrimental effects. In this context, the effects of the anti-inflammatory agent meloxicam have been scarcely documented after stroke, but its ability to inhibit both cyclooxygenase isoforms (1 and 2) could be a promising strategy to modulate post-ischemic inflammation. This study analyzed the effect of the anti-inflammatory agent meloxicam in a transient focal ischemia model in rats, measuring its neuroprotective effect after 48 hours and 7 days of reperfusion and the effects of the treatment on the glial scar and regenerative events such as the generation of new progenitors in the subventricular zone and axonal sprouting at the edge of the damaged area. We show that meloxicam’s neuroprotective effects remained after 7 days of reperfusion even if its administration was restricted to the two first days after ischemia. Moreover, meloxicam treatment modulated glial scar reactivity, which matched with an increase in axonal sprouting. However, this treatment decreased the formation of neuronal progenitor cells. This study discusses the dual role of anti-inflammatory treatments after stroke and encourages the careful analysis of both the neuroprotective and the regenerative effects in preclinical studies. Abstract Figure:
- 12 November 2020
- Published by Springer Nature in Molecular Neurobiology
- Vol. 58 (4) , 1404-1417
Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome
Stroke is one of the main causes of death and disability worldwide. Ischemic stroke results in unfolded/misfolded protein accumulation in endoplasmic reticulum (ER), a condition known as ER stress. We hypothesized that previously reported neuroprotection of celecoxib, a selective inhibitor of cyclooxygenase-2, in transient middle cerebral artery occlusion (tMCAO) model, relies on the ER stress decrease. To probe this hypothesis, Sprague-Dawley rats were subjected to 1 h of tMCAO and treated with celecoxib or vehicle 1 and 24 h after ischemia. Protein and mRNA levels of the main hallmarks of ER stress, unfolded protein response (UPR) activation, UPR-induced cell death, and ubiquitin proteasome system (UPS) and autophagy, the main protein degradation pathways, were measured at 12 and 48 h of reperfusion. Celecoxib treatment decreased polyubiquitinated protein load and ER stress marker expression such as glucose-related protein 78 (GRP78), C/EBP (CCAAT/enhancer-binding protein) homologous protein (CHOP), and caspase 12 after 48 h of reperfusion. Regarding the UPR activation, celecoxib promoted inositol-requiring enzyme 1 (IRE1) pathway instead of double-stranded RNA-activated protein kinase-like ER kinase (PERK) pathway. Furthermore, celecoxib treatment increased proteasome catalytic subunits transcript levels and decreased p62 protein levels, while the microtubule-associated protein 1 light chain 3 (LC3B) II/I ratio remained unchanged. Thus, the ability of celecoxib treatment on reducing the ER stress correlates with the enhancement of IRE1-UPR pathway and UPS degradation. These data support the ability of anti-inflammatory therapy in modulating ER stress and reveal the IRE1 pathway as a promising therapeutic target in stroke therapy. Graphical abstract
- 12 November 2020
- Published by Springer Nature in Molecular Neurobiology
- Vol. 58 (4) , 1404-1417
Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome
Stroke is one of the main causes of death and disability worldwide. Ischemic stroke results in unfolded/misfolded protein accumulation in endoplasmic reticulum (ER), a condition known as ER stress. We hypothesized that previously reported neuroprotection of celecoxib, a selective inhibitor of cyclooxygenase-2, in transient middle cerebral artery occlusion (tMCAO) model, relies on the ER stress decrease. To probe this hypothesis, Sprague-Dawley rats were subjected to 1 h of tMCAO and treated with celecoxib or vehicle 1 and 24 h after ischemia. Protein and mRNA levels of the main hallmarks of ER stress, unfolded protein response (UPR) activation, UPR-induced cell death, and ubiquitin proteasome system (UPS) and autophagy, the main protein degradation pathways, were measured at 12 and 48 h of reperfusion. Celecoxib treatment decreased polyubiquitinated protein load and ER stress marker expression such as glucose-related protein 78 (GRP78), C/EBP (CCAAT/enhancer-binding protein) homologous protein (CHOP), and caspase 12 after 48 h of reperfusion. Regarding the UPR activation, celecoxib promoted inositol-requiring enzyme 1 (IRE1) pathway instead of double-stranded RNA-activated protein kinase-like ER kinase (PERK) pathway. Furthermore, celecoxib treatment increased proteasome catalytic subunits transcript levels and decreased p62 protein levels, while the microtubule-associated protein 1 light chain 3 (LC3B) II/I ratio remained unchanged. Thus, the ability of celecoxib treatment on reducing the ER stress correlates with the enhancement of IRE1-UPR pathway and UPS degradation. These data support the ability of anti-inflammatory therapy in modulating ER stress and reveal the IRE1 pathway as a promising therapeutic target in stroke therapy. Graphical abstract